Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of $1.74, $3.06 better than the analyst estimate of ($1.32). Revenue for the quarter came in at $750.5 million versus the consensus estimate of $397.99 million.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.